Don Tracy, Associate Editor

PrEPVacc halts study of experimental HIV vaccine regimens and a new form of oral pre-exposure prophylaxis.

DREAMM-7 was a Phase 3, multicenter, open-label, randomized trial analyzing the efficacy and safety of Blenrep plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously administered at least one prior line of treatment.

Study aims to find ways industry gets involved in the most influential clinical trials, and how transparent these trials are.

Medication focuses on the acute treatment of migraines.

Study emphasizes role in bridging research and development and commercial/marketing functions.

Findings suggests implementation could save time and money, but needs to be evaluated carefully.

Studies with Zenith-CKD showed significant albuminuria reduction.

BI 690517 is a novel, potent, highly selective aldosterone synthase inhibitor that reduces the progression of kidney damage and lowers the risk of cardiovascular events in patients with chronic kidney disease.

SLS009 is a novel CDK9 inhibitor under investigation for the treatment of relapsed/refractory peripheral T-cell lymphomas.

Furmonertinib is in development for the treatment of advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations.

Breakout session challenges current creation methods.

Steve Rosenberg, CEO, uMotif, discusses how patients would like to be involved in clinical trials as innovations in digital technologies continue to evolve.

Session discusses next steps to advancing evidence generation systems.

SCOPE session discusses key challenges of evaluating potential providers.

Panel at SCOPE discusses applying novel evidence in regulatory decision-making.

Panel at SCOPE discusses the possibilities of research in a post-COVID world.